<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>25522859</identifier>
<setSpec>1576-6578</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ruiz, Lara</dc:author>
<dc:author>Muñoz, Irene</dc:author>
<dc:author>Domínguez, Elena</dc:author>
<dc:author>Uribe, Fernando</dc:author>
<dc:author>Ruiz-Piñero, Marina</dc:author>
<dc:author>Hernández, Marta S</dc:author>
<dc:author>Guerrero-Peral, Ángel L</dc:author>
<dc:author>Toribio-Díaz, M Elena</dc:author>
<dc:description xml:lang="en">INTRODUCTION Sexual dysfunctions are one of the most important problems affecting sexual health and are associated with low levels of quality of life. AIM To assess the sexual functioning in migraine patients and the sexual dysfunction that can be attributed to its preventive treatment. PATIENTS AND METHODS The patients attended in the headache units of two general hospitals who visited for the first time after being prescribed preventive treatment. They answered the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) and the Psychotropic-Related Sexual Dysfunction Questionnaire (SALSEX). RESULTS The sample used in the study consisted of 79 patients (17 males, 62 females) aged 37.6 ± 9.1 years (range: 19-57 years), 31 (39.2%) of them with chronic migraine. As preventive treatment, 23 (29.1%) received beta blockers; 42 (53.2%) neuromodulators; 8 (10.1%), calcium antagonists; and 6 (7.6%), antidepressants. The MGH-SFQ detected diminished overall sexual satisfaction that was at least moderate in 24 patients (30.4%). SALSEX showed changes in sexual functioning that was attributable to the preventive treatment in 36 cases (45.5%), which only exceptionally appeared spontaneously. In patients with at least moderate dysfunction on the MGH-SFQ, the mean ages at the time of testing, the number of days with pain per month and the excessive use of medication for their symptoms were all higher (53.3% versus 46.7%; p = 0.03). CONCLUSIONS Simple sexual dysfunction screening tests often detect sexual dysfunctions in patients with migraine on preventive treatment and changes in their sex life that can be attributed to these drugs.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2015 Jan 01 </dc:date>
<dc:title xml:lang="es">Disfuncion sexual en pacientes migrañosos que reciben tratamiento preventivo: identificacion mediante dos tests de cribado.</dc:title>
<dc:description xml:lang="es">
             Disfuncion sexual en pacientes migrañosos que reciben tratamiento preventivo: identificacion mediante dos tests de cribado. 
             Introduccion. Las disfunciones sexuales constituyen uno de los problemas mas importantes que afectan a la salud sexual y se asocian a bajos niveles de calidad de vida. Objetivo. Evaluar la funcion sexual en pacientes migrañosos y la disfuncion sexual atribuible al tratamiento preventivo. Pacientes y metodos. Pacientes atendidos en las consultas de cefaleas de dos hospitales generales que acudian a la primera visita tras prescripcion de un preventivo. Respondieron al cuestionario de funcionamiento sexual del Hospital General de Massachusetts (MGH-SFQ) y al cuestionario de disfuncion sexual secundaria a psicofarmacos (SALSEX). Resultados. Muestra de 79 pacientes (17 varones, 62 mujeres), de 37,6 ± 9,1 años (rango: 19-57 años), 31 (39,2%) de ellos con migraña cronica. Como tratamiento preventivo, 23 (29,1%) recibian betabloqueantes; 42 (53,2%), neuromoduladores; 8 (10,1%), antagonistas del calcio, y 6 (7,6%), antidepresivos. El MGH-SFQ detecto en 24 pacientes (30,4%) disminucion al menos moderada de satisfaccion sexual global. El SALSEX mostro cambio de la funcion sexual atribuible al tratamiento preventivo en 36 casos (45,5%), solo excepcionalmente manifestada de forma espontanea. En pacientes con disfuncion al menos moderada en el MGH-SFQ, eran significativamente mayores la edad media en el momento de la inclusion, el numero de dias de dolor al mes y el uso excesivo de medicacion sintomatica (53,3% frente a 46,7%; p = 0,03). Conclusion. La disfuncion sexual evaluada con sencillos test de cribado detecta con frecuencia disfuncion sexual en pacientes migrañosos en tratamiento preventivo y cambios en su vida sexual atribuibles a estos farmacos. 
        </dc:description>
<dc:title xml:lang="en">[Sexual dysfunction in migraine patients who receive preventive treatment: identification by means of two screening tests].</dc:title>
<dc:publisher>Revista de neurologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
